HCV-related cryoglobulinemic glomerulonephritis: Implications of antiviral and immunosuppressive therapies

Acta Biomedica de l'Ateneo Parmense

Volumn 78, Issue 1, 2007, Pages

  Garini, Giovanni ^a,b   Allegri, Landino ^a   Iannuzzella, Francesco ^a   Vaglio, Augusto ^a   Buzio, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Hepatitis C virus; Interferon ; Membranoproliferative glomerulonephritis; Mixed cryoglobulinemia; Ribavirin; Rituximab

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; RITUXIMAB;

ADULT; AGED; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CRYOGLOBULINEMIA; DRUG DOSE REDUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LABORATORY TEST; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 34447498448     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Agnello V, De Rosa F. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40: 341-52.
2. Brouet JC, Clauvel JP, Danon F, Lein M, Seligmann M. Biologic and clinical significance of cryoglobulins: A report of 86 cases. Am J Med 1974; 57: 775-88.
3. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992; 38: 798-802.
4. Pascual M, Perrin L, Giostra E, Schifferli J. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162: 569-70.
5. Ferri C, Greco F, Longobardo G, et al. Association between hepatitis C virus and mixed cryoglobulinaemia. Clin Exp Rheumatol 1991; 9: 621-4 .
6. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
7. Choo Q, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
8. Trejo O, Ramos-Casals M, Garcìa-Carrasco M, et al. Cryoglobulinemia. Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine 2001; 80: 252-62.
9. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine (Baltimore) 2000; 79: 47-56.
10. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. Q J Med 1995; 88: 115-26.
11. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathological diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94-102.
12. Ferri C, Greco F, Longobardo G, et al. Association between hepatitis C virus and mixed cryoglobulinaemia. Clin Exp Rheumatol 1991; 9: 621-4 .
13. Monteverde A, Ballare M, Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopathol 1997; 19: 99-110.
14. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
15. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia. A clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
16. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287-308.
17. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999; 42: 2507-16.
18. D'Amico G. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis induced by hepatitis C virus. Kidney Int 1998; 54: 650-71.
19. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-70.
20. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine 2002; 81: 398-409.
21. Fornasieri A, D'Amico G. Type II mixed cryoglobulinaemia, hepatitis C virus infection, and glomerulonephritis. Nephrol Dial Transplant 1996; 11 (Suppl 4): 25-30.
22. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.
23. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
24. Mazzaro C, Panarello G, Tesio F, et al. Hepatitis C virus risk: a hepatitis C virus related syndrome. J Int Med 2000; 247: 535-45.
25. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-4.
26. Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25: 67-9.
27. Sarac E, Bastacky S, Johnson JP. Response to high dose interferon-α after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30: 113-5.
28. Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinemic glomerulonephritis with a combination of interferon-α and ribavirin. Nephrol Dial Transplant 1999; 14: 1558-60.
29. Garini G, Allegri L, Camevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E35.
30. Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113: 516-9.
31. Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-41.
32. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002; 6: 909-13.
33. Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia. J Infect 1998; 36: 229-30.
34. Otha S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33: 1040-8.
35. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histological data. Am J Med 1983; 75: 382-91.
36. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
37. Cordonnier D, Martin H, Groslambert P, Micouin C, Chenais F, Stoebner P. Mixed IgG-IgM cryoglobulinaemia with glomerulonephritis. Immunochemical fluorescent and ultrastructural study of kidney and in vivo cryoprecipitate. Am J Med 1975; 59: 867-72 .
38. Sinico AR, Winearls CG, Sabadini E, Fornasieri A, Castiglioni A, D'Amico G. Identification of glomerular immune deposits in cryoglobulinaemia glomerulonephritis. Kidney Int 1988; 34: 1-8.
39. Feiner H, Gallo G. Ultrastructure in glomerulonephritis associated with cryoglobulinemia. Am J Pathol 1977; 88: 145-62.
40. Stoebner P, Renversez JC, Groulde J, Vialtel P, Cordonnier D. Ultrastructural study of human IgG and IgG-IgM crystalcryoglobulins. Am J Clin Pathol 1979; 71: 404-10.
41. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
42. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46: 585-97.
43. McHutchison JG, Hoofnagle JH. Therapy of chronic hepatitis C. In Liang TJ, Hoofnagle JH (eds): Hepatitis C. San Diego: Academic Press, 2000: 203-39.
44. Lopes E, Lopes LV, Silva AE. Mixed cryoglobulinemia and membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Ann Intern Med 1996; 125: 781-2.
45. Campise M, Tarantino A. Glomerulonephritis in mixed cryoglobulinemia: what treatment? Nephrol Dial Transplant 1999; 14: 281-3.
46. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-9.
47. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Treatment of mixed cryoglobulinemia resistant to interferon-alpha with an anti-CD 20 monoclonal antibody. Blood 2003; 101: 3818-26.
48. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
49. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-61.